Urine Test Distinguish Malignant And Benign Adrenal Tumors

Urine Test Distinguish Malignant And Benign Adrenal Tumors
A global analysis of metabolites and small molecules in urine samples from patients with adrenal cancer has identified four biochemicals that, when measured together, can distinguish malignant from benign adrenal tumors. The results of the study was published in the Journal of the American College of Surgeons and presented at the 2015 Annual Clinical Congress of the American College of Surgeons.

Findings from the study may help surgeons more confidently decide how to treat patients who have signs of adrenal masses on radiologic imaging but no symptoms of adrenal disease. Such patients are considered to have adrenal incidentalomas. Adrenal incidentalomas are the most common type of abnormality discovered on imaging studies that are performed for conditions unrelated to the adrenal gland. The abnormalities are found in about 3 percent of people older than 50 years of age and about 4 percent of all computed tomography scans performed in the general population.
Most adrenal incidentalomas can be managed conservatively because they are small and do not affect the release of hormones from the gland. However, about 5 percent of these lesions require prompt surgery because they are suspected to be cancerous. Guidelines on the management of adrenal incidentalomas recommend surgical removal of the adrenal gland when a lesion is 4 cm or larger in diameter or it exhibits radiologic characteristics suggestive of cancer, such as traces of calcium.
These clinical signs are not definitively associated with cancer. Rather, they indicate the patient has an increased risk of an adrenal malignancy. "Up until now, there have been no metabolomic markers to tell us whether an adrenal lesion is cancerous or not," the researchers said.
The researchers conducted a study to determine if a noninvasive urinary test could help diagnose adrenal cancer by detecting differences in small molecules in the body. They obtained urine specimens from 19 patients with adrenal cortical carcinoma and 46 patients with benign adrenal tumors and ran a global analysis of all metabolites to detect differences in the two groups. A total of 67 biochemical features discriminated cancer from benign tumors in these samples, but only four specific metabolites could be considered as biomarkers for cancer: creatinine riboside, tryptophan, Nε, Nε, Nε-trimethyllysine, and 3-methylhistidine. When these metabolites were present in characteristic patterns in urine samples, they were highly sensitive and specific for carcinoma.
The metabolites could successfully identify cancer in 94.7 percent of cases and rule out the disease 82.6 percent of the time. In comparison, adrenal lesions greater than 4 cm in diameter have a sensitivity of 93 percent and a specificity of only 42 percent for cancer.
The study also found that the four metabolites had a high likelihood of predicting which patients had cancer and which did not. The positive predictive rate was 69.2, and the negative predictive rate was 97.4.
The researchers are obtaining more urine samples as well as serum to validate the results of this study. Down the line, they hope their investigations will lead surgeons to use global small molecule urinalysis as an adjunct to the standard radiologic workup of patients with incidental adrenalomas.
Based on material originally posted by American College of Surgeons.